1. Home
  2. VMD vs LUNG Comparison

VMD vs LUNG Comparison

Compare VMD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$7.25

Market Cap

280.4M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.21

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
LUNG
Founded
2006
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.4M
63.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VMD
LUNG
Price
$7.25
$2.21
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
156.7K
1.1M
Earning Date
11-05-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
35.92
N/A
EPS
0.34
N/A
Revenue
$254,794,000.00
$91,664,000.00
Revenue This Year
$20.05
$9.21
Revenue Next Year
$17.44
$5.03
P/E Ratio
$21.70
N/A
Revenue Growth
18.89
15.59
52 Week Low
$5.93
$1.31
52 Week High
$8.62
$9.37

Technical Indicators

Market Signals
Indicator
VMD
LUNG
Relative Strength Index (RSI) 58.99 52.99
Support Level $7.31 $2.43
Resistance Level $7.68 $2.65
Average True Range (ATR) 0.20 0.21
MACD 0.02 -0.00
Stochastic Oscillator 62.31 46.48

Price Performance

Historical Comparison
VMD
LUNG

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: